

# Programme ESWI2025, 19-23 October 2025, Valencia, Spain

[Sun 19 Oct 2025](#) [Mon 20 Oct 2025](#) [Tue 21 Oct 2025](#) [Wed 22 Oct 2025](#) [Thu 23 Oct 2025](#) [Programme chairs](#)

## SUN 19 OCT 2025

17:00 - 20:00

**POSTER MOUNTING** REG02  
Poster Halls

**REGISTRATION DESK OPEN** REG01  
Registration desk

## MON 20 OCT 2025

09:00 - 18:00

**REGISTRATION DESK OPEN** REG03  
Registration desk

10:00 - 11:00

**PLENARY OPENING AND KEYNOTES** PLE01  
Auditorium 1 - Plenary Hall

PLE

CHAIRS



**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands



**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany



**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy



**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

**Opening word by the conference chairs: The 10th ESWI Influenza Conference**

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

**Opening address by the Spanish Minister of Health**

**Mónica GARCÍA GÓMEZ** Spanish Ministry of Health, Spain

**Long Covid**

**Peter OPENSHAW** ESWI Board Member, Imperial College, United Kingdom

**H5N1 bovine outbreaks in the USA**

**Stacey SCHULTZ-CHERRY** St Jude Children's Research Hospital, United States

**Closing remarks**

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany

**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

11:00 - 11:30

**COFFEE BREAK** COF01  
Exhibition hall

**POSTER MOUNTING** REG04  
Poster Halls

11:30 - 13:00

**INNATE AND ADAPTIVE IMMUNITY** SCS01  
Auditorium 1 - Plenary Hall

SCS



CHAIRS



**Guus RIMMELZWAAN** University of Veterinary Medicine, Hannover, Germany



**Kevin SELVA** Doherty Institute, University of Melbourne, Australia

Opening of the session

**Guus RIMMELZWAAN** University of Veterinary Medicine, Hannover, Germany

**Kevin SELVA** Doherty Institute, University of Melbourne, Australia

1. **Increasing SARS-CoV-2 IgG4 following repeated mRNA boosters negatively impact antibody functions across Omicron variants and sarbecoviruses**

**Kevin SELVA** Doherty Institute, University of Melbourne, Australia

2. **Impact of Aging on CD8+ T Cell Immunity to Circulating and Pandemic Viruses**

**Carolien VAN DE SANDT** ESWI Associate Member, Murdoch Children's Research Institute, Melbourne, Australia

3. **Detection of pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals**

**Christoph KREER** University of Cologne, Germany

4. **Systemic and mucosal antibody signatures of protection against sars-cov-2 transmission**

**Amaya ROJO FERNANDEZ** Icahn School of Medicine at Mount Sinai, United States

5. **Obesity modulates tracheal and cardiac responses to influenza A virus infection**

**Betina Lyngfeldt HENRIKSEN** Technical University of Denmark, Denmark

6. **Prior influenza vaccination shapes subsequent vaccine responses in a randomized placebo-controlled trial**

**Marcos VIEIRA** University of Chicago, United States

Closing remarks

**Guus RIMMELZWAAN** University of Veterinary Medicine, Hannover, Germany

**Kevin SELVA** Doherty Institute, University of Melbourne, Australia

PANDEMIC PREPAREDNESS SCS02

Auditorium 2 - Breakout

SCS

CHAIRS



**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany



**Nico Joel HALWE** Ludwig Boltzmann Gesellschaft, Austria

Opening of the session

**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany

**Nico Joel HALWE** Ludwig Boltzmann Gesellschaft, Austria

1. **Observed Immunogenicity After Two Doses of an MF59-Adjuvanted Cell Culture-Derived H5N8 Influenza Vaccine (aH5N8c) in Healthy Subjects Aged ≥18 Years**

**Janine OBERIJE** CSL R&D - Vaccines Innovation Unit, Netherlands

2. **Immunogenicity of Homologous or Heterologous Booster Vaccinations with MF59-Adjuvanted, Cell Culture-Derived H5N8 or H5N6 Influenza Vaccines in Healthy Subjects Aged ≥18 Years**

**Eve VERSAGE** CSL Seqirus, United States

3. **When can sequence data confirm transmission links in respiratory virus outbreaks?**

**Simon DE JONG** Amsterdam University Medical Centers, Netherlands

4. **Broad-Spectrum Baseline Immunity Against Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Viruses in Dutch Healthcare Workers: Insights into Both Humoral and Cellular Immune Responses**

**Mark POWER** Erasmus Medical Center, Netherlands

5. **Evaluating Cross-Protective Antibody Responses to Influenza A(H5N8) Vaccine in High-Risk Groups**

**Oona LIEDES** Finnish Institute for Health and Welfare, Finland

6. **OVX836, a Nucleoprotein based vaccine under clinical development, offers protection against Highly Pathogenic Avian Influenza viruses (H5N1 and H7N9) in mouse and ferret models**

**Charlotte PRIMARD** Osivax, France



Closing remarks

**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany

**Nico Joel HALWE** Ludwig Boltzmann Gesellschaft, Austria

ESWI INVITES COALITION PARTNERS: LIFE COURSE IMMUNISATION: A SEAMLESS APPROACH TO PROTECTION ACROSS ALL AGES **SPI01**

SPI

Auditorium 3 - Breakout

CHAIRS



**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy



**Catherine WEIL OLIVIER** independent expert, Trustee of CLCI, France

Understanding life course immunisation

**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

**Catherine WEIL OLIVIER** independent expert, Trustee of CLCI, France

Age-specific immunisation needs and challenges

**Paula TÄHTINEN** ESWI Board Member, Turku University Hospital and University of Turku, Finland

**Nicola VERONESE** Unicamillus University, Italy

Burden of disease

**Catherine MOORE** Public Health Wales, United Kingdom

Nurses and Pharmacists as Immunisation Champions

**George KASSIANOS** ESWI Board Member, United Kingdom

**Lars-Åke SÖDERLUND** International Pharmaceutical Federation, Sweden

Barriers & Solutions for Seamless Life Course Immunisation: Interactive Discussion

**Catherine WEIL OLIVIER** independent expert, Trustee of CLCI, France

**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

**Paula TÄHTINEN** ESWI Board Member, Turku University Hospital and University of Turku, Finland

**Nicola VERONESE** Unicamillus University, Italy

**Catherine MOORE** Public Health Wales, United Kingdom

**George KASSIANOS** ESWI Board Member, United Kingdom

**Lars-Åke SÖDERLUND** International Pharmaceutical Federation, Sweden

Call to Action and Closing Remarks

**Catherine WEIL OLIVIER** independent expert, Trustee of CLCI, France

**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

13:00 - 14:30

LUNCH **LUN01**

Exhibition hall

POSTER MOUNTING **REG05**

Poster Halls

13:15 - 14:15

SATELLITE SYMPOSIUM ORGANISED BY ASTRAZENECA: UNFOLDING THE STORY OF THE IMMUNE RESPONSE TO AN INTRANASAL LIVE ATTENUATED INFLUENZA VACCINE **SAT01**

SAT

Auditorium 2 - Breakout

CHAIR



**Peter OPENSHAW** ESWI Board Member, Imperial College, United Kingdom

Welcome and introduction

**Peter OPENSHAW** ESWI Board Member, Imperial College, United Kingdom

MOVE-ing forward: towards a better understanding of mucosal immunity and correlates of protection for a live attenuated influenza vaccine

**Yper HALL** UKHSA, United Kingdom

Mucosal immunity matters: mechanistic insights into a live attenuated influenza vaccine

**Ryan THWAITES** National Heart and Lung Institute, Imperial College London, United Kingdom



Beyond antigenic match: optimizing candidate virus strain selection for a live attenuated influenza vaccine

**Oliver DIBBEN** AstraZeneca, United Kingdom

Q&A and meeting close

**Peter OPENSHAW** ESWI Board Member, Imperial College, United Kingdom

14:30 - 16:00

## FUTURE VACCINATION STRATEGIES - PART 1 SCS03

SCS

Auditorium 1 - Plenary Hall

CHAIRS



**Florian KRAMMER** ESWI Board Member, Medical University of Vienna, Austria



**Yona TUGG** McMaster University, Canada

Opening of the session

**Florian KRAMMER** ESWI Board Member, Medical University of Vienna, Austria

**Yona TUGG** McMaster University, Canada

1. A Dendritic Cell-targeting Approach to Deliver a Universal Influenza Vaccine Candidate to the Respiratory Mucosa

**Daryl LEE** National University of Singapore, Singapore

2. Development of a next-generation COVID-19 intranasal vaccine based on a multivalent NDV-HXP-S formulation.

**Marta BOZA CUENCA** Icahn School of Medicine at Mount Sinai, United States

3. Superior protection and prevention of transmission upon influenza infection by adjuvanted mucosal vaccination in the guinea pig influenza model.

**Michael SCHOTSAERT** Icahn School of Medicine at Mount Sinai, United States

4. Broad betacoronavirus immunity and SARS-CoV-2 protection induced by divergent spike-based nucleoside-modified vaccines

**Anass ABBAD** Icahn Medical School at Mount Sinai, United States

5. The Additive Effect of Neuraminidase Inclusion in Influenza Vaccine Formulations using a Self-Amplifying RNA Platform

**Giuseppe PALLADINO** CSL, United States

6. Evaluation of a broadly protective influenza B virus vaccine based on mosaic hemagglutinin platforms in mice.

**Irene GONZÁLEZ-DOMÍNGUEZ** Icahn School of Medicine at Mount Sinai, United States

Closing remarks

**Florian KRAMMER** ESWI Board Member, Medical University of Vienna, Austria

**Yona TUGG** McMaster University, Canada

## VIRUS AND HOST FACTORS IN PATHOGENESIS - PART 1 SCS04

SCS

Auditorium 2 - Breakout

CHAIRS



**Debby VAN RIEL** ESWI Associate Member, Erasmus MC, Netherlands



**Anders MADSEN** Haukeland University Hospital, Norway

Opening of the session

**Debby VAN RIEL** ESWI Associate Member, Erasmus MC, Netherlands

**Anders MADSEN** Haukeland University Hospital, Norway

1. Avian influenza viruses re-shape the hormonal landscape by inducing pulmonary CYP19A1 expression in golden hamsters

**Sebastian BECK** Leibniz Institute of Virology, Germany

2. Obesity increases the risk for severe COVID 19 – An obese hamster model to study sex-specific differences in the underlying pathophysiology

**Zoé SCHMAL** Leibniz Institute of Virology, Germany

3. Functional Balance of HA and NA in Emerging Porcine Influenza A Viruses: Sialoreceptor Dynamics at the Mucosal Interface

**Mengying LIU** Utrecht University, Netherlands



4. Cell Tropism, Replication Dynamics, and effect on neural network activity to Seasonal and Pandemic Influenza A Virus Infection in a hiPSC-Derived Neural Co-Culture Model

**Feline BENAVIDES** Erasmus MC, Netherlands

5. Single-cell profiling of inflammatory lung injury in clade 2.3.4.4b H5N1 influenza infected mice

**Ying LIU** The University of Hong Kong, Hong Kong SAR China

6. A history of obesity increases influenza severity via innate immune training in a canonical NLRP3-dependent manner

**Katina HULME** Amsterdam UMC, Netherlands

Closing remarks

**Debby VAN RIEL** ESWI Associate Member, Erasmus MC, Netherlands

**Anders MADSEN** Haukeland University Hospital, Norway

**BURDEN OF DISEASE IN ACUTE RESPIRATORY VIRUS INFECTIONS** SPI02

Auditorium 3 - Breakout

SPI

CHAIRS



**Paula TÄHTINEN** ESWI Board Member, Turku University Hospital and University of Turku, Finland



**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

Welcome and introduction

**Paula TÄHTINEN** ESWI Board Member, Turku University Hospital and University of Turku, Finland

**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

Overview of burden of disease in acute respiratory viruses

**Ivan SANZ-MUÑOZ** Instituto de Estudios de Ciencias de la Salud de Castilla y León, Spain

1. Risk factors associated with severe health outcomes among older adults hospitalized with respiratory syncytial virus (RSV): understanding the pre-vaccine era landscape

**Vajini ATUKORALE** University of Toronto, Canada

Respiratory infections and associated long-term complications

**Fiona ECARNOT** University Hospital Besancon, France

Global Status of Adult Immunisation Post COVID-19

**Alba VILAJELIU** WHO, Switzerland

Panel discussion

**Paula TÄHTINEN** ESWI Board Member, Turku University Hospital and University of Turku, Finland

**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

**Fiona ECARNOT** University Hospital Besancon, France

**Alba VILAJELIU** WHO, Switzerland

**Vajini ATUKORALE** University of Toronto, Canada

Closing remarks

**Paula TÄHTINEN** ESWI Board Member, Turku University Hospital and University of Turku, Finland

**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

16:00 - 16:30

**COFFEE BREAK** COF02

Exhibition hall

**POSTER MOUNTING** REG06

Poster Halls

16:30 - 17:30

**SATELLITE SYMPOSIUM ORGANISED BY NOVAVAX: THE STRATEGIC VALUE OF ADJUVANTS IN VACCINE DEVELOPMENT** SAT02

Auditorium 1 - Plenary Hall

SAT

CHAIR



**Ruxandra DRAGHIA-AKLI** Novavax, Inc., United States

The Strategic Value of Adjuvants in Vaccine Development

**Ruxandra DRAGHIA-AKLI** Novavax, Inc., United States



Chijioke BENNETT Novavax, Inc, United States

SATELLITE SYMPOSIUM ORGANISED BY PFIZER: PREVENTING RSV DISEASE IN ADULTS: A VACCINATION SUCCESS STORY SAT03

SAT

Auditorium 2 - Breakout

CHAIR



**Jorge DEL DIEGO SALAS** General Directorate of Public Health and Health Equity of the Ministry of Health of Spain, Spain

Welcome and Introduction

**Jorge DEL DIEGO SALAS** General Directorate of Public Health and Health Equity of the Ministry of Health of Spain, Spain

RSV Disease in Adults: The Hidden Burden and Advancing Prevention

**Giovanni CHECCUCCI LISI** PFIZER, Italy

RSV Disease Prevention: A Story of Success in the UK

**George KASSIANOS** ESWI Board Member, United Kingdom

Beyond Respiratory Protection: Latest Real-World Evidence for the Bi-valent RSVpreF Vaccine (DAN-RSV)

**Mats C. Højbjerg LASSEN** Herlev og Gentofte Hospital, Denmark

Summary and Q&A

**Jorge DEL DIEGO SALAS** General Directorate of Public Health and Health Equity of the Ministry of Health of Spain, Spain

SATELLITE SYMPOSIUM ORGANISED BY THE ESWI IDC AND SUPPORTED BY IFPMA AND SANOFI: WHEN INFECTIONS MEET NCDs: THE BIDIRECTIONAL RELATIONSHIP BETWEEN CARDIOMETABOLIC CONDITIONS AND RESPIRATORY VIRUSES SAT11

SAT

Auditorium 3 - Breakout

CHAIR



**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

The Bidirectional Relationship Between Cardiometabolic Conditions and Respiratory Viruses why and now?

**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

1. When Glucose Swings Matter: Glycemic Variability and Influenza Outcomes in Critically Ill Patients

**Ramon FLUIT** Spaarne Ziekenhuis: Spaarne Gasthuis, Netherlands

From Evidence to Gaps: Chronic Conditions Shaping Outcomes in Respiratory Virus Infections what we know, don't know and want to know

**Kirsty SHORT** ESWI Associate Member, University of Queensland, Australia

Obesity's Impact on Infection & Vaccination response; Could obesity be the key link connecting NCDs and increased susceptibility to respiratory infections

**Stacey SCHULTZ-CHERRY** St Jude Children's Research Hospital, United States

From Infection to NCD and Back: Clinical Implications of a Bidirectional Relationship

**Oana SANDULESCU** Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases Prof Dr Matei Bals, Romania

Barriers to Vaccination Uptake in High-Risk Groups – and Practical Advice for Clinicians and Policymakers

**Eric C.M. VAN GORP** Erasmus MC, Netherlands

Questions and discussion with the audience and panellists

**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

17:30 - 19:00

WELCOME REFRESHMENTS AND NETWORKING DIN01

Exhibition hall

18:30 - 20:00

EARLY CAREER SCIENTISTS WORKSHOP - COMMUNICATING SCIENCE - INVITATION ONLY - WITH THE SUPPORT OF CSL SEQIRUS AND SANOFI ECAS01

ECAS

External



08:15 - 09:15

## SATELLITE SYMPOSIUM: : A SHOT IN THE ARM: LEVERAGING COMBINATION VACCINES FOR GLOBAL HEALTH IMPACT (A PEERVOICE SYMPOSIUM SUPPORTED BY AN EDUCATIONAL GRANT FROM MODERNA) SAT05

Auditorium 2 - Breakout

SAT

### Welcome and introductions

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

### The Power of Combination: A New Era in Vaccination

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

### The Persistent Threat of COVID-19 and Influenza – Why Smarter Vaccination Strategies Are Essential

**John WATKINS** Cardiff University/Public Health Wales, United Kingdom

### Harnessing mRNA Innovation to Advance Combination Vaccines and Improve Uptake

**John WATKINS** Cardiff University/Public Health Wales, United Kingdom

### The Case for Combination Vaccines

**Gili REGEV-YOCHAY** Sheba Medical Center, Tel Aviv University, Israel

### Ask the Faculty and Take-Home Messages

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

**John WATKINS** Cardiff University/Public Health Wales, United Kingdom

**Gili REGEV-YOCHAY** Sheba Medical Center, Tel Aviv University, Israel

09:30 - 10:30

## SCIENCE, PUBLIC HEALTH, AND FUNDING IN A CHANGING WORLD PLE02

Auditorium 1 - Plenary Hall

PLE

### CHAIRS



**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany



**Joseph BRESEE** Task Force for Global Health, United States

### Introduction to the session

**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany

**Joseph BRESEE** Task Force for Global Health, United States

### Short presentations and panel discussion

**Florian KRAMMER** ESWI Board Member, Medical University of Vienna, Austria

**Peter MARKS** Independent Consultant, United States

**Carolien VAN DE SANDT** ESWI Associate Member, Murdoch Children's Research Institute, Melbourne, Australia

**Frederic BOUDER** University of Stavanger, Norway

**Nick BUNDLE** ECDC, Sweden

**Angela RASMUSSEN** University of Saskatchewan, Canada

10:30 - 11:00

## COFFEE BREAK COF03

Exhibition hall

11:00 - 12:30

## EPIDEMIOLOGY AND SURVEILLANCE SCS05

Auditorium 1 - Plenary Hall

SCS

### CHAIRS



**Nick BUNDLE** ECDC, Sweden



**Marco DEL RICCIO** University of Florence, Italy

### Opening of the session

**Nick BUNDLE** ECDC, Sweden

**Marco DEL RICCIO** University of Florence, Italy



1. Age at First Influenza A Virus Infection in Children and Impact of Influenza Vaccination

**Kayla HANSON** University of Michigan School of Public Health, United States

2. Association of influenza viral genetic information with disease severity markers in hospitalized patients

**Aung Pone MYINT** UCBL1, France

3. Population-based Surveillance shows Burden of Hospitalisations and Severe Disease due to hMPV, RSV, and Influenza in Older Adults

**Alejandro ORRICO-SÁNCHEZ** Fisabio-Public Health, Spain

4. Impact of COVID-19 non-pharmaceutical interventions on antibody waning and the resurgence of human respiratory syncytial virus, seasonal coronavirus and influenza virus in a prospective cohort in The Netherlands

**Channah GAASBEEK** RIVM, Netherlands

5. Epidemiology of hospitalizations in older adults with lab-confirmed hMPV infection: A 14-year time series

**Ivan SANZ-MUÑOZ** Instituto de Estudios de Ciencias de la Salud de Castilla y León, Spain

6. Epidemiology of human coronaviruses and impact of SARS-CoV-2 vaccination in paediatric patients in Hong Kong

**Zirui GUO** The University of Hong Kong, Hong Kong SAR China

Closing remarks

**Nick BUNDLE** ECDC, Sweden

**Marco DEL RICCIO** University of Florence, Italy

MOLECULAR VIROLOGY: VIRUS EVOLUTION, STRAIN SELECTION, STRUCTURE AND REPLICATION

SCS16

SCS

Auditorium 2 - Breakout

CHAIRS



**Sylvie VAN DER WERF** ESWI Associate Member, Institut Pasteur, France



**Jurre SIEGERS** Institut Pasteur du Cambodge, Cambodia

Opening of the session

**Sylvie VAN DER WERF** ESWI Associate Member, Institut Pasteur, France

**Jurre SIEGERS** Institut Pasteur du Cambodge, Cambodia

1. Antigenic drift in the receptor binding site of H1N1 balances antibody evasion and receptor binding

**Jenna GUTHMILLER** University of Colorado Anschutz Medical Campus, United States

2. HA Mutations Driving Immune Escape in Avian Influenza Virus Do Not Enhance Human Receptor Binding

**Elsayed ABDEL-WHAB** Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Germany

3. Multivalent Colocalization of Influenza Polymerase and Nucleoprotein by ANP32A Reveals the Molecular Basis of Human Adaptation

**Aldo Roman CAMACHO ZARCO** CEA, France

4. Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase

**Ron FOUCHIER** Erasmus MC, Netherlands

5. Little evidence for additional mammalian adaptation in bovine-derived H5N1 viruses during replication or transmission in ferrets

**Heather MACHKOVECH** University of Wisconsin, United States

Closing remarks

**Sylvie VAN DER WERF** ESWI Associate Member, Institut Pasteur, France

**Jurre SIEGERS** Institut Pasteur du Cambodge, Cambodia

HOW SCIENTIFIC EVIDENCE GUIDES POLICY: LESSONS LEARNED SPI03

Auditorium 3 - Breakout

SPI

CHAIRS



**Joseph BRESEE** Task Force for Global Health, United States



**Ann MOEN** Task Force for Global Health, United States



Preventing RSV infections in infants: vaccines and monoclonal antibodies

**Federico MARTINÓN TORRES** Hospital Clínico Universitario de Santiago de Compostela, Spain  
**Ignacio ESTEBAN** Gavi, the Vaccine Alliance, Switzerland

NITAGs and Evidence for Influenza Vaccine Recommendations in Middle Income Countries

**Lisandro TORRE** Task Force for Global Health, United States  
**Stephen HADLER** Task Force for Global Health, United States  
**Silvia BINO** SECID INSTITUTE OF PUBLIC HEALTH ALBANIA, Albania

12:30 - 14:00

**LUNCH** LUN02  
Exhibition hall

12:45 - 13:45

**SATELLITE SYMPOSIUM ORGANISED BY SANOFI: AIM HIGH, SHOOT THE FLU WITH A BETTER SHOT!** SAT06  
Auditorium 2 - Breakout

SAT

Welcome and introduction

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Real-world evidence (RWE) for influenza vaccine effectiveness: The GOOD and the BAD!

**Mathieu BANGERT** Sanofi, France

Results and learnings from the largest ever individually randomised influenza vaccine effectiveness study: FLUNITY-HD

**Federico MARTINÓN TORRES** Hospital Clínico Universitario de Santiago de Compostela, Spain

Panel discussion and closing remarks

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands  
**Mathieu BANGERT** Sanofi, France  
**Federico MARTINÓN TORRES** Hospital Clínico Universitario de Santiago de Compostela, Spain

14:00 - 15:30

**PHARMACEUTICAL AND NON PHARMACEUTICAL INTERVENTIONS** SCS07  
Auditorium 1 - Plenary Hall

SCS

CHAIRS



**Benjamin COWLING** The University of Hong Kong, Hong Kong SAR China



**Nisreen OKBA** Icahn School of Medicine at Mount Sinai, United States

Opening of the session

**Benjamin COWLING** The University of Hong Kong, Hong Kong SAR China  
**Nisreen OKBA** Icahn School of Medicine at Mount Sinai, United States

1. Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg Based Influenza Vaccines During the 2023–2024 Season in the United States

**Alicia STEIN** CSL Seqirus, Australia

2. Effectiveness of 2024/25 COVID-19 vaccines against symptomatic SARS-CoV-2 infection in the target group for vaccination, European VEBIS primary care multicentre study, autumn/winter 2024/25

**Esther KISSLING** Epiconcept, France

3. Differential protection of prior infection and repeated vaccination against SARS-CoV-2 infection in Omicron BA.2 to JN.1 predominance: a prospective cohort study

**Nicole Ngai Yung TSANG** The University of Hong Kong, Hong Kong SAR China

4. Vaccine effectiveness against medically attended influenza at primary care level in the paediatric population, 2024/25 season, Europe

**Héloïse LUCACCIONI** Epiconcept, France

5. Immunogenicity and safety of high dose formulations of mf59-adjuvanted cell-derived influenza vaccine in adults aged 50 years and older: two phase 2 randomised controlled trials

**Frank ALBANO** CSL Seqirus, Australia

6. High-dose recombinant influenza vaccines induce greater A(H3N2)-reactive antibodies and overcome attenuation associated with repeated vaccination compared to standard-dose egg- or cell-based vaccines: results from a RCT in healthy younger adults

**Sheena SULLIVAN** Monash University, Australia



#### Closing remarks

**Benjamin COWLING** The University of Hong Kong, Hong Kong SAR China

**Nisreen OKBA** Icahn School of Medicine at Mount Sinai, United States

## MATHEMATICAL MODELLING AND PROJECTIONS, INCLUDING LIMITATIONS SCS08

Auditorium 2 - Breakout

SCS

#### CHAIRS



**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands



**Weijia XIONG** The University of Hong Kong, Hong Kong SAR China

#### Opening of the session

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

**Weijia XIONG** The University of Hong Kong, Hong Kong SAR China

#### 1. A Framework for Measuring Population Immunity Against Influenza Using Individual Antibody Titers

**Weijia XIONG** The University of Hong Kong, Hong Kong SAR China

#### 2. serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data

**Adam KUCHARSKI** London School of Hygiene & Tropical Medicine, United Kingdom

#### 3. Integrating Serology and PCR to Infer RSV Infection Dynamics and Correlates of Protection in a Community Cohort in The Gambia

**Thushan DE SILVA** University of Sheffield, United Kingdom

#### 4. Joint reconstruction of influenza A(H1N1) and A(H3N2) antibody dynamics to estimate the risk of influenza virus infection

**Tim TSANG** The University of Hong Kong, Hong Kong SAR China

#### 5. Investigating the predictive power of machine learning algorithms for antigenic novelty of influenza H3 viruses

**Lucy GREENWOOD** University of Oxford, United Kingdom

#### 6. Comparative Pre-symptomatic Transmission Potential of Influenza A and SARS-CoV-2 in Households

**Chengyao ZHANG** University of Hong Kong, Hong Kong SAR China

#### Closing remarks

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

**Weijia XIONG** The University of Hong Kong, Hong Kong SAR China

## IMPLEMENTATION OF ADULT AND RISK GROUPS NATIONAL IMMUNISATION PROGRAMMES SPI

SPI04

Auditorium 3 - Breakout

SPI

#### CHAIRS



**Ted VAN ESSEN** ESWI Board Member, Netherlands



**George KASSIANOS** ESWI Board Member, United Kingdom

#### Introduction to the session

**Ted VAN ESSEN** ESWI Board Member, Netherlands

**George KASSIANOS** ESWI Board Member, United Kingdom

#### 1. Effectiveness of Maternal Influenza Vaccination in Preventing Influenza Infection in Infants Aged $\leq 6$ Months in Korea

**Yoonsun YOON** Korea University Guro Hospital, South Korea

#### 2. Preliminary observation of impact of Maternal RSV Vaccination on Infant Hospitalizations in Mendoza, Argentina: A Comparative Study of the 2023 and 2024 Seasons

**Juan Manuel FERNANDEZ MUÑOZ** Ministry of Health of Mendoza, Argentina

#### Implementing Adult Vaccination in Europe: Lessons from the AIB Meeting

**Marco DEL RICCIO** University of Florence, Italy

#### Strengthening Immunisation Systems for Equity and Resilience in the WHO European Region

**Oleg BENES** WHO RO for Europe, Denmark



SPI Roundtables in Europe Lessons from Czech Republic and Austria

**Roman PRYMULA** ESWI Board Member, Postgraduate Medical School, Czechia

**Florian KRAMMER** ESWI Board Member, Medical University of Vienna, Austria

Discussion and wrap up

**Ted VAN ESSEN** ESWI Board Member, Netherlands

**George KASSIANOS** ESWI Board Member, United Kingdom

**Yoonsun YOON** Korea University Guro Hospital, South Korea

**Juan Manuel FERNANDEZ MUÑOZ** Ministry of Health of Mendoza, Argentina

**Marco DEL RICCIO** University of Florence, Italy

**Oleg BENES** WHO RO for Europe, Denmark

**Florian KRAMMER** ESWI Board Member, Medical University of Vienna, Austria

**Roman PRYMULA** ESWI Board Member, Postgraduate Medical School, Czechia

15:30 - 16:00

COFFEE BREAK COF04

Exhibition hall

16:00 - 17:00

SATELLITE SYMPOSIUM ORGANISED BY CSL SEQIRUS: ADDRESSING THE EVOLVING INFLUENZA LANDSCAPE: A PUBLIC HEALTH IMPERATIVE SAT07

SAT

Auditorium 2 - Breakout

CHAIR



**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Navigating change: Current challenges with preventable respiratory viruses

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Targeting age-related immune decline with enhanced influenza vaccines

**Paolo BONANNI** University of Florence, Italy

Advancing technologies for influenza prevention in children and adults

**Tino SCHWARZ** Klinikum Wuerzburg Mitte, Germany

Final remarks and Q&A

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

**Paolo BONANNI** University of Florence, Italy

**Tino SCHWARZ** Klinikum Wuerzburg Mitte, Germany

17:00 - 18:30

POSTER PRESENTATIONS "TEST TUBES" AND REFRESHMENTS POS01

POS

Poster Halls

18:30 - 19:30

EARLY CAREER SCIENTISTS EVENT AND PANEL DISCUSSION "LIFE AFTER PHD" - INVITATION ONLY - WITH THE SUPPORT OF ASTRAZENECA, CSL SEQIRUS AND SANOFI ECAS02

ECAS

External

WED 22 OCT 2025

08:15 - 09:15

SATELLITE SYMPOSIUM ORGANISED BY THE GLOBAL INFLUENZA INITIATIVE: PREVENTING INFLUENZA TO SAFEGUARD AGEING POPULATIONS SAT08

SAT

Auditorium 2 - Breakout

CHAIR



**Litjen (L.J) TAN** Co-Chair of the Global Influenza Initiative; Immunize.org, United States

Welcome and setting the scene

**Litjen (L.J) TAN** Co-Chair of the Global Influenza Initiative; Immunize.org, United States

Navigating the 2024-2025 flu season: insights on severity, vaccine uptake and impact

**Litjen (L.J) TAN** Co-Chair of the Global Influenza Initiative; Immunize.org, United States



**Mine DURUSU TANRIOVER** Director of Vaccine Institute, Hacettepe University, Türkiye

**Understanding what shapes influenza vaccine decisions by HCPs and patients**

**Salah AL AWAI** Public Health Consultant, Oman

**Litjen (L.J) TAN** Co-Chair of the Global Influenza Initiative; Immunize.org, United States

**Mine DURUSU TANRIOVER** Director of Vaccine Institute, Hacettepe University, Türkiye

**George KASSIANOS** ESWI Board Member, United Kingdom

**Strengthening partnerships for lifelong wellness**

**Salah AL AWAI** Public Health Consultant, Oman

**Litjen (L.J) TAN** Co-Chair of the Global Influenza Initiative; Immunize.org, United States

**Mine DURUSU TANRIOVER** Director of Vaccine Institute, Hacettepe University, Türkiye

**George KASSIANOS** ESWI Board Member, United Kingdom

**Summary and close**

**Litjen (L.J) TAN** Co-Chair of the Global Influenza Initiative; Immunize.org, United States

09:30 - 10:30

**KEYNOTE LECTURES** PLE03

Auditorium 1 - Plenary Hall

PLE

**CHAIR**



**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

**From Questions to Insights: Advancing Respiratory Virus Epidemiology in the Spirit of John Paget**

**Marco DEL RICCIO** University of Florence, Italy

**Silent reservoirs for long term consequences of ARVI**

**Gülsah GABRIEL** ESWI Board Member, Leibniz Institute of Virology, Germany

**Understanding Viral and Antibody Kinetics to Strengthen Influenza and COVID-19 Surveillance and Control**

**Adam KUCHARSKI** London School of Hygiene & Tropical Medicine, United Kingdom

10:30 - 11:00

**COFFEE BREAK** COF05

Exhibition hall

11:00 - 12:30

**FUTURE VACCINATION STRATEGIES - PART 2** SCS09

Auditorium 1 - Plenary Hall

SCS

**CHAIRS**



**Florian KRAMMER** ESWI Board Member, Medical University of Vienna, Austria



**Marios KOUTSAKOS** University of Melbourne, Australia

**Opening of the session**

**Florian KRAMMER** ESWI Board Member, Medical University of Vienna, Austria

**Marios KOUTSAKOS** University of Melbourne, Australia

**1. A Novel Antigenically Central HA mRNA Vaccine Confers Humoral and Cellular Immune Responses and Protects Ferrets Against Challenge With a Heterologous A(H5) Clade 2.3.4.4b Highly Pathogenic Avian Influenza Virus**

**Willemijn RIJNINK** Erasmus MC, Netherlands

**2. Breast milk-derived secretory IgA provides broad protection against influenza A virus**

**Yona TUGG** McMaster University, Canada

**3. Hemagglutination inhibition antibody titer as correlate of protection against influenza virus infection: a systematic review and meta-analysis**

**Nancy H. L. LEUNG** The University of Hong Kong, Hong Kong SAR China

**4. Pooled Long-Term Safety Analysis of a Phase 1/2/3 Randomized, Observer-Blind, Controlled Study of the Self-Amplifying mRNA COVID-19 Vaccine ARCT-154 in Adults**

**Josephine VAN BOXMEER** CSL Seqirus, Netherlands

**5. Decades of Evidence Revisited: A Systematic Review on Anti-Neuraminidase Antibody Responses and Influenza-related Outcomes**

**Clotilde SÉBLAIN** Sanofi vaccines, France



6. Immunogenicity and Reactogenicity of an mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine (mRNA-1083) in Adults ≥65 Years With Comorbidities

**Lusine KOSTANYAN** Moderna, Inc., United States

Closing remarks

**Florian KRAMMER** ESWI Board Member, Medical University of Vienna, Austria

**Marios KOUTSAKOS** University of Melbourne, Australia

HUMAN CHALLENGE STUDIES SCS11

Auditorium 2 - Breakout

SCS

CHAIR



**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany

Opening of the session

**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany

1. Disease characteristics and immunological profiles obtained from a newly developed hMPV human challenge model

**Brandon LONDT** hVIVO, United Kingdom

2. Evolution of Human Metapneumovirus (HMPV) over the last 20 years and superior isolation of HMPV from clinical samples in organoid-derived bronchial cell cultures to isolation in monolayer cell line cultures

**Bernadette VAN DEN HOOGEN** ErasmusMC, Netherlands

3. A Study of the Efficacy, Safety and Immunogenicity of mRNA vaccines in an Influenza B Challenge Model in Healthy Adults

**Anita GEEVARUGHESE** Pfizer, United States

4. Development of a Severe Acute Respiratory Syndrome – Coronavirus 2 (SARS-CoV-2) Omicron BA5 human challenge model (HCM) for the assessment of new vaccine and anti-viral therapies in seropositive subjects

**Alex MANN** hVIVO, United Kingdom

5. Establishing a Controlled Human Infection Model with a contemporary Respiratory Syncytial Virus B challenge agent in healthy volunteers

**Victor CNOSSEN** Centre for Human Drug Research, Netherlands

Closing remarks

**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany

CLINICAL MANIFESTATIONS, BURDEN OF DISEASE AND MANAGEMENT SCS10

Auditorium 3 - Breakout

SCS

CHAIRS



**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands



**Valentino D'ONOFRIO** Ghent University, Belgium

Opening of the session

**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

**Valentino D'ONOFRIO** Ghent University, Belgium

1. Burden of Influenza Hospitalisation (Including With Recent COVID-19) Among Individuals With Immunocompromising Conditions and Other Comorbidities: An Exploratory Analysis Using the INFORM Study Cohort

**Wilhelmine MEERAUS** AstraZeneca, United Kingdom

2. Is clinical outcome pathogen related? Characteristics and Outcomes of ICU Patients with Severe Acute Respiratory Infections: Focusing on Respiratory Syncytial Virus, Human Metapneumovirus, Influenza virus, and Parainfluenza virus

**Sjoerd VAN DER BIE** Spaarne Gasthuis, Netherlands

3. Hospital Burden of Respiratory Syncytial Virus (RSV) in Adults Aged 18 to 60 Years in France: A Nationwide Analysis (2018–2023)

**Clarisse DEMONT** Moderna, France

4. Clinical outcomes among older adults hospitalized with respiratory syncytial virus and influenza infection – a retrospective study from Israel

**Michal MANDELBOIM** Israel Ministry of Health, Israel

5. The Effect of Revaccination and Reinfection on Symptom Severity and Prevalence in a Post Covid-19 Condition Cohort



**Emma VAN DER SPEK** National Institute for Public Health and the Environment (RIVM), Netherlands

6. **RSV in Patients with Hematological Malignancies: A Multi-centre Retrospective Cohort Study**

**Justin DUTOIT** Wits Donal Gordon Medical Center, South Africa

Closing remarks

**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

**Valentino D'ONOFRIO** Ghent University, Belgium

12:30 - 14:00

**LUNCH** LUN03

Exhibition hall

12:45 - 13:45

**SATELLITE SYMPOSIUM COMMUNICATING FOR CHANGE – INNOVATIVE STRATEGIES TO BOOST ADULT IMMUNISATION (AN ESWI SYMPOSIUM SUPPORTED BY AN EDUCATIONAL GRANT FROM GSK)** SAT09

SAT

Auditorium 2 - Breakout

CHAIR



**Frederic BOUDER** University of Stavanger, Norway

Introduction and scope of the session

**Frederic BOUDER** University of Stavanger, Norway

Silent Signals: Structural Ageism, Vaccine Policy, and the Call for Reciprocal Communication

**Jane BARRATT** Dr Jane Barratt Consulting Inc, Canada

Trust as Infrastructure: Equity, Empathy, and Evidence in Shaping Sustainable Immunisation Strategies

**Rodrigo SCOTINI** Infectious Disease Alliance (IDA), Denmark

Grassroots Mobilisation Leveraging Civil Society and Community Leadership to Bridge Gaps in Vaccine Coverage

**Mariano VOTTA** Active Citizenship Network, Italy

Embedding Vaccine Communication in Everyday Health: Lessons from EU Initiatives

**Barbara RATH** Vaccine Safety Initiative, Germany

Panel and Audience Exchange: Addressing Structural Ageism, Trust, and Vaccine Confidence

**Barbara RATH** Vaccine Safety Initiative, Germany

**Jane BARRATT** Dr Jane Barratt Consulting Inc, Canada

**Rodrigo SCOTINI** Infectious Disease Alliance (IDA), Denmark

**Mariano VOTTA** Active Citizenship Network, Italy

14:00 - 15:30

**ANTIVIRAL AND IMMUNE THERAPY** SCS12

SCS

Auditorium 1 - Plenary Hall

CHAIRS



**Adolfo GARCÍA-SASTRE** Icahn School of Medicine at Mount Sinai, United States



**Josefine SCHROEDER** Jena University Hospital, Germany

Opening of the session

**Adolfo GARCÍA-SASTRE** Icahn School of Medicine at Mount Sinai, United States

**Josefine SCHROEDER** Jena University Hospital, Germany

1. Effectiveness of the approved antiviral drugs for mild/moderate infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Hong Kong

**George OKOLI** The University of Hong Kong, Hong Kong SAR China

2. Impact of Antiviral Timing and Vaccination on Viral Shedding in Hospitalized Older Adults with COVID-19 During Omicron Predominance

**Yun LIN** World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China, Hong Kong SAR China

3. Analysis of potential drug combinations against influenza by specifically targeting the viral polymerase

**Bahaeldin ALHAMMADY** Leibniz-Institut für Virologie (LIV), Germany

4. Treatment with pictilisib-loaded lipid nanoparticles reduces influenza A virus infection in vitro and ex vivo



**Josefine SCHROEDER** Jena University Hospital, Germany

5. Comparative assessment of in vivo antiviral activity of anti-influenza drugs (AD ASTRA)

**Podjane JITTAMALA** Mahidol University, Thailand

6. Structural characterization and preclinical development of a heavy chain-only antibody that protects against group 1 and group 2 influenza A viruses

**Xavier SAELENS** Ghent University and VIB, Belgium

Closing remarks

**Adolfo GARCÍA-SASTRE** Icahn School of Medicine at Mount Sinai, United States

**Josefine SCHROEDER** Jena University Hospital, Germany

VIRUS EVOLUTION AND STRAIN SELECTION SCS13

Auditorium 2 - Breakout

SCS

CHAIRS



**Kirsty SHORT** ESWI Associate Member, University of Queensland, Australia



**Kairat TABYNOV** Kazakh National Agrarian Research University, Kazakhstan

Opening of the session

**Kirsty SHORT** ESWI Associate Member, University of Queensland, Australia

**Kairat TABYNOV** Kazakh National Agrarian Research University, Kazakhstan

Avian influenza in Australia's native avifauna

**Kirsty SHORT** ESWI Associate Member, University of Queensland, Australia

1. Antigenic mapping of influenza A viruses using deep learning-based prediction of hemagglutination inhibition titers

**Bingyi YANG** The University of Hong Kong, Hong Kong SAR China

2. Site specific predictability of amino acid substitutions of seasonal influenza viruses

**Annelies DE ROOIJ** Amsterdam University Medical Center, Netherlands

3. Informal settlements and COVID-19: viral phylogenetic, respiratory microbiome, and public health implications.

**Mercedes Soledad NABAES JODAR** Ricardo Gutierrez Children Hospital, Argentina

4. Understanding the evolution of Influenza A/H3N2 polymerase complex

**Carla LOURENS** Amsterdam UMC - Locatie AMC, Netherlands

Closing remarks

**Kirsty SHORT** ESWI Associate Member, University of Queensland, Australia

**Kairat TABYNOV** Kazakh National Agrarian Research University, Kazakhstan

TRANSDISCIPLINARY APPROACHES FOR PANDEMIC PREPAREDNESS SPI05

Auditorium 3 - Breakout

SPI

CHAIR



**Ed HUTCHINSON** ESWI Board Member, University of Glasgow, United Kingdom

Introduction to the session

**Ed HUTCHINSON** ESWI Board Member, University of Glasgow, United Kingdom

Leibniz Lab Pandemic Preparedness - a German Initiative for Pandemic Preparedness

**Gülsah GABRIEL** ESWI Board Member, Leibniz Institute of Virology, Germany

The Pandemic and Disaster Preparedness Center (PDPC) as a Dutch Initiative for Pandemic Preparedness

**Ron FOUCHIER** Erasmus MC, Netherlands

Epistemic Exclusion in Science Communication

**Mona SIMION** University of Glasgow, United Kingdom

Prepared Together: Co-Creative Research for Future Pandemics

**Sabine MAASEN** Universität Hamburg, Germany

Panel discussion



**Gülsah GABRIEL** ESWI Board Member, Leibniz Institute of Virology, Germany

**Sabine MAASEN** Universität Hamburg, Germany

**Mona SIMION** University of Glasgow, United Kingdom

**Ron FOUCHIER** Erasmus MC, Netherlands

Closing remarks

**Ed HUTCHINSON** ESWI Board Member, University of Glasgow, United Kingdom

15:30 - 16:00

**COFFEE BREAK** COF06  
Exhibition hall

16:00 - 17:30

**THREATS FROM THE ANIMAL WORLD** SCS14 PLE  
Auditorium 1 - Plenary Hall

SCS

CHAIRS



**Stacey SCHULTZ-CHERRY** St Jude Children's Research Hospital, United States



**Kevin CIMINSKI** University Medical Center Freiburg, Germany

Opening of the session

**Stacey SCHULTZ-CHERRY** St Jude Children's Research Hospital, United States

**Kevin CIMINSKI** University Medical Center Freiburg, Germany

Keynote address: **Zoonotic Influenza: Emerging Threats from the Animal World**

**Martin BEER** Friedrich-Loeffler-Institut, Germany

1. **Genomic insights into the broadening host range of clade 2.3.4.4b H5 avian influenza viruses**

**Alice FUSARO** Istituto Zooprofilattico Sperimentale delle Venezie, Italy

2. **Emergence of a Novel Reassortant Clade 2.3.2.1e Avian Influenza A/H5N1 Virus Associated with Human Cases in Cambodia**

**Jurre SIEGERS** Institut Pasteur du Cambodge, Cambodia

3. **Increased attachment to and replication of recent avian H5N1 influenza A viruses from clade 2.3.4.4b in human airway epithelial cells**

**Lisa BAUER** Erasmus MC, Netherlands

4. **Bovine Myxovirus Resistance Protein 1 mediates antiviral activity against human and avian influenza A viruses**

**Rubaiyea FARRUKEE** University of Melbourne, Australia

Closing remarks

**Stacey SCHULTZ-CHERRY** St Jude Children's Research Hospital, United States

**Kevin CIMINSKI** University Medical Center Freiburg, Germany

17:30 - 19:00

**POSTER PRESENTATIONS "MICROSCOPES" AND REFRESHMENTS** POS02  
Poster Halls

POS

**THU 23 OCT 2025**

08:15 - 09:15

**SATELLITE SYMPOSIUM ORGANISED BY PFIZER: UNLOCKING THE VALUE OF VACCINES AS A TOOL TO SUPPORT THE MANAGEMENT OF NON-COMMUNICABLE DISEASES (NCDS)** SAT10  
Auditorium 1 - Plenary Hall

SAT

CHAIR



**Jane BARRATT** Dr Jane Barratt Consulting Inc, Canada

Welcome and introduction

**Jane BARRATT** Dr Jane Barratt Consulting Inc, Canada

The burden of co-circulating vaccine-preventable respiratory diseases

**Charles FELDMAN** University of the Witwatersrand, Australia



The impact of vaccine-preventable respiratory infections on non-communicable diseases

**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

Advocacy levers to help drive vaccine uptake in eligible populations

**Michael MOORE** World Federation of Public Health Associations, Australia

Audience Q&A and Panel Discussion

**Jane BARRATT** Dr Jane Barratt Consulting Inc, Canada

SATELLITE SYMPOSIUM ORGANISED BY THE ENDFLU PROJECT: EVALUATION OF RATIONALLY DESIGNED INFLUENZA VACCINES - EU HORIZON 2020 RESEARCH AND INNOVATION

SAT

PROGRAMME SAT12

Auditorium 2 - Breakout

CHAIR



**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany

Development of Modified Vaccinia virus Ankara (MVA)-based influenza vaccines for pandemic preparedness targeting hemagglutinin of selected influenza A virus subtypes

**Alina TSCHERNE** Medical University of Vienna, Austria

Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses

**Guus RIMMELZWAAN** University of Veterinary Medicine, Hannover, Germany

Influenza A virus NA as an antiviral target

**Xander DE HAAN** Utrecht University, Netherlands

SATELLITE SYMPOSIUM ORGANISED BY ISRV: 20TH ANNIVERSARY OF ISRV LECTURE SAT04

SAT

Auditorium 3 - Breakout

CHAIR



**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

1. The use of antivirals in pandemics: what have we learnt?

**Maria ZAMBON** UK Health Security Agency (UKHSA), United Kingdom

09:30 - 10:30

EARLY CAREER SCIENTIST AWARDS AND PRESENTATIONS ECAS03 PLE

ECAS

Auditorium 1 - Plenary Hall

CHAIRS



**Carolien VAN DE SANDT** ESWI Associate Member, Murdoch Children's Research Institute, Melbourne, Australia



**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

Award Ceremony

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

**Carolien VAN DE SANDT** ESWI Associate Member, Murdoch Children's Research Institute, Melbourne, Australia

DEI Awards Science Slam

**Fiseha Wadilo WADA** Armaour Hansen Research Institute, Ethiopia

**Shiyamalee ARUNASALAM** University of Peradeniya, Sri Lanka

**Aida ABBASI** ReNAp company, Iran

**Noroso Harline RAZANAJATOVO** Institut Pasteur de Madagascar, Madagascar

**Sètondji Islamiath KISSIRA** National Laboratory of Hemorrhagics and Virals Fevers of Bénin (LFHV), Benin

Another receptor, another tropism: Lessons from bats as influenza A virus reservoirs

**Kevin CIMINSKI** University Medical Center Freiburg, Germany

Antigenic evolution of influenza B viruses

**Marios KOUTSAKOS** University of Melbourne, Australia

10:30 - 11:00



11:00 - 12:30

VIRUS STRUCTURE AND REPLICATION SCS06

SCS

Auditorium 1 - Plenary Hall

CHAIRS



**Ed HUTCHINSON** ESWI Board Member, University of Glasgow, United Kingdom



**Lisa BAUER** Erasmus MC, Netherlands

Opening of the session

**Ed HUTCHINSON** ESWI Board Member, University of Glasgow, United Kingdom

**Lisa BAUER** Erasmus MC, Netherlands

1. Proteomic analysis of the subcellular reorganization during Influenza A infection in human cells

**Laura GADEA-SALOM** BIOTECMED, Universitat de València, Spain

2. Influenza NS1-Mediated N(6)-Methyladenosine Modification Controls NS mRNA Splicing

**Yingyin LIAO** The University of Hong Kong, Hong Kong SAR China

3. Reassortment dynamics between clade 2.3.2.1 and 2.3.4.4b A(H5) influenza viruses

**Lorin ADAMS** The Francis Crick Institute, United Kingdom

4. Human respirovirus infection driven by heteromultivalent binding of sialoglycotopes

**Xander DE HAAN** Utrecht University, Netherlands

5. RSV Polymerase L Recruits Rab11a to Facilitate Ribonucleoprotein Transport

**Marie-Anne RAMEIX-WELTI** Institut Pasteur CNR Vir (Bat Jacob, France)

6. Transient RNA structure-driven insertions in H5 hemagglutinin required for highly pathogenic avian influenza virus genesis are not dependent on polymerase origin.

**Roy M. HUTCHINSON** Erasmus MC, Netherlands

Closing remarks

**Ed HUTCHINSON** ESWI Board Member, University of Glasgow, United Kingdom

**Lisa BAUER** Erasmus MC, Netherlands

VIRUS AND HOST FACTORS IN PATHOGENESIS - PART 2 SCS17

SCS

Auditorium 2 - Breakout

CHAIRS



**Ron FOUCHIER** Erasmus MC, Netherlands



**Mengying LIU** Utrecht University, Netherlands

Opening of the session

**Ron FOUCHIER** Erasmus MC, Netherlands

**Mengying LIU** Utrecht University, Netherlands

1. Respiratory Syncytial Virus G Protein Enhances Viral Dissemination Through TLR2-NFκB-Mediated NLRP3 Priming and Pyroptotic Cell Death

**Robert MEINEKE** University of Veterinary Medicine Hannover, Germany

2. Reverse Zoonosis Shapes Transmission and Virulence of Recent H5N1 Clade 2.3.4.4b in Diverse Bird Species

**Elsayed ABDEL-WHAB** Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Germany

3. Autoantibodies against type I IFNs in patients with zoonotic H7N9 infection

**Martin SCHWEMMLE** University of Freiburg, Germany

4. Revealing Fc-functional antibody landscapes in COVID-19

**Teresa AYDILLO GOMEZ** Icahn School of Medicine of Mount Sinai Hospital, United States

5. Knockdown of Irf9 within vagal sensory ganglia exacerbates disease severity during pulmonary influenza A viral infection

**Nathalie VERZELE** University of Melbourne, Belgium



6. Genome-wide CRISPR/Cas9 screen identifies host factors potentially modulating influenza A virus polymerase fidelity

**Hui Min LEE** The Roslin Institute, United Kingdom

Closing remarks

**Ron FOUCHIER** Erasmus MC, Netherlands

**Mengying LIU** Utrecht University, Netherlands

12:30 - 14:00

FAREWELL BUFFET LUNCH LUN04

Exhibition hall

14:00 - 15:30

LATE BREAKERS: NOVEL AND OUTSTANDING DISCOVERIES SCS15 PLE

SCS

Auditorium 1 - Plenary Hall

CHAIRS



**Sylvie VAN DER WERF** ESWI Associate Member, Institut Pasteur, France



**Carolien VAN DE SANDT** ESWI Associate Member, Murdoch Children's Research Institute, Melbourne, Australia

Opening of the session

**Sylvie VAN DER WERF** ESWI Associate Member, Institut Pasteur, France

**Carolien VAN DE SANDT** ESWI Associate Member, Murdoch Children's Research Institute, Melbourne, Australia

1. mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 Years, Including Individuals at High Risk for Severe Disease

**Rituparna DAS** Moderna Therapeutics, United States

2. A real-life study revealed the presence of more than 10% nirsevimab escape mutants in RSV-B breakthrough infections.

**Marie-Anne RAMEIX-WELTI** Institut Pasteur CNR Vir (Bat Jacob, France)

3. Adjuvanted inactivated zoonotic influenza A(H5N8) vaccination induces antibody and T-cell responses to emerging HPAI clade 2.3.4.4b A(H5N1) viruses in healthcare workers

**Rory DE VRIES** Erasmus MC, Netherlands

4. Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study

**Voon ONG** Cidara, United States

5. Effectiveness of HD-IIIV against laboratory-confirmed influenza infection and patient-centered outcomes in the community: a DANFLU-2 sub-study

**Filip Soeskov DAVIDOVSKI** Herlev and Gentofte Hospital, Denmark

6. Novel Drug-Antigen Conjugate EV25: Results from a First-in-Human Phase 1/2a Trial in Healthy Volunteers and H3N2 Influenza Challenge Participants - Safety, Pharmacokinetics and Antiviral Activity

**Jeffery NIELSEN** Eradivir, United States

Closing remarks

**Sylvie VAN DER WERF** ESWI Associate Member, Institut Pasteur, France

**Carolien VAN DE SANDT** ESWI Associate Member, Murdoch Children's Research Institute, Melbourne, Australia

15:40 - 15:55

KEYNOTE LECTURE PLE05

PLE

Auditorium 1 - Plenary Hall

CHAIR



**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

The FLUNITY-HD study, a prespecified pooled analysis of the DANFLU-2 and GALFLU trials

**Tor BIERING-SØRENSEN** University of Copenhagen, Denmark

16:00 - 16:20

CLOSING REMARKS PLE04

PLE

Auditorium 1 - Plenary Hall

CHAIRS



**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands



**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany





**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy



**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

**Closing remarks and reveal of the 11th ESWI Conference location**

**Colin RUSSELL** ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands

**Ab OSTERHAUS** ESWI Board Member, TiHO, Germany

**Marco GOEIJENBIER** ESWI Board Member, Spaarne Gasthuis, Netherlands

**Stefania MAGGI** ESWI Board Member, National Research Council of Italy, Italy

## Programme chairs



BIO

**Ab OSTERHAUS**

ESWI BOARD MEMBER, TIHO, GERMANY



BIO

**Adolfo GARCÍA-SASTRE**

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, UNITED STATES



BIO

**Anders MADSEN**

HAUKELAND UNIVERSITY HOSPITAL, NORWAY



BIO

**Ann MOEN**

TASK FORCE FOR GLOBAL HEALTH, UNITED STATES



BIO

**Benjamin COWLING**

THE UNIVERSITY OF HONG KONG, HONG KONG SAR CHINA



BIO

**Carolien VAN DE SANDT**

ESWI ASSOCIATE MEMBER, MURDOCH CHILDREN'S RESEARCH INSTITUTE, MELBOURNE, AUSTRALIA



BIO

**Catherine WEIL OLIVIER**

INDEPENDENT EXPERT, TRUSTEE OF CLCI, FRANCE



BIO

**Colin RUSSELL**

ESWI BOARD MEMBER, ACADEMIC MEDICAL CENTER, UNIVERSITY OF AMSTERDAM, NETHERLANDS



BIO

**Debby VAN RIEL**

ESWI ASSOCIATE MEMBER, ERASMUS MC, NETHERLANDS



BIO

**Ed HUTCHINSON**

ESWI BOARD MEMBER, UNIVERSITY OF GLASGOW, UNITED KINGDOM



BIO

**Florian KRAMMER**

ESWI BOARD MEMBER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA



BIO

**Frederic BOUDER**

UNIVERSITY OF STAVANGER, NORWAY



BIO

**George KASSIANOS**

ESWI BOARD MEMBER, UNITED KINGDOM



BIO

**Guus RIMMELZWAAN**

UNIVERSITY OF VETERINARY MEDICINE, HANNOVER, GERMANY



BIO

**Jane BARRATT**

DR JANE BARRATT CONSULTING INC, CANADA



BIO

**Jorge DEL DIEGO SALAS**

GENERAL DIRECTORATE OF PUBLIC HEALTH AND HEALTH EQUITY OF THE MINISTRY OF HEALTH OF SPAIN, SPAIN



BIO

**Josefine SCHROEDER**

JENA UNIVERSITY HOSPITAL, GERMANY



BIO

**Joseph BRESEE**

TASK FORCE FOR GLOBAL HEALTH, UNITED STATES



BIO

**Jurre SIEGERS**

INSTITUT PASTEUR DU CAMBODGE, CAMBODIA



BIO

**Kairat TABYNOV**

KAZAKH NATIONAL AGRARIAN RESEARCH UNIVERSITY, KAZAKHSTAN



BIO

**Kevin CIMINSKI**

UNIVERSITY MEDICAL CENTER FREIBURG, GERMANY



BIO

**Kevin SELVA**

DOHERTY INSTITUTE, UNIVERSITY OF MELBOURNE, AUSTRALIA



BIO

**Kirsty SHORT**

ESWI ASSOCIATE MEMBER, UNIVERSITY OF QUEENSLAND, AUSTRALIA



BIO

**Lisa BAUER**

ERASMUS MC, NETHERLANDS



BIO

**Litjen (L.J) TAN**

CO-CHAIR OF THE GLOBAL INFLUENZA INITIATIVE; IMMUNIZE.ORG, UNITED STATES





BIO

**Marco DEL RICCIO**

UNIVERSITY OF FLORENCE, ITALY



BIO

**Marco GOEIJENBIER**

ESWI BOARD MEMBER, SPAARNE GASTHUIS, NETHERLANDS



BIO

**Marios KOUTSAKOS**

UNIVERSITY OF MELBOURNE, AUSTRALIA



BIO

**Mengying LIU**

UTRECHT UNIVERSITY, NETHERLANDS



BIO

**Nick BUNDLE**

ECDC, SWEDEN



BIO

**Nico Joel HALWE**

LUDWIG BOLTZMANN GESELLSCHAFT, AUSTRIA

**Nisreen OKBA**

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, UNITED STATES



BIO

**Paula TÄHTINEN**

ESWI BOARD MEMBER, TURKU UNIVERSITY HOSPITAL AND UNIVERSITY OF TURKU, FINLAND



BIO

**Peter OPENSHAW**

ESWI BOARD MEMBER, IMPERIAL COLLEGE, UNITED KINGDOM



BIO

**Ron FOUCHIER**

ERASMUS MC, NETHERLANDS



BIO

**Ruxandra DRAGHIA-AKLI**

NOVAVAX, INC., UNITED STATES



BIO

**Stacey SCHULTZ-CHERRY**

ST JUDE CHILDREN'S RESEARCH HOSPITAL, UNITED STATES



BIO

**Stefania MAGGI**

ESWI BOARD MEMBER, NATIONAL RESEARCH COUNCIL OF ITALY, ITALY



BIO

**Sylvie VAN DER WERF**

ESWI ASSOCIATE MEMBER, INSTITUT PASTEUR, FRANCE



BIO

**Ted VAN ESSEN**

ESWI BOARD MEMBER, NETHERLANDS



BIO

**Valentino D'ONOFRIO**

GHENT UNIVERSITY, BELGIUM



BIO

**Weijia XIONG**

THE UNIVERSITY OF HONG KONG, HONG KONG SAR CHINA



BIO

**Yona TUGG**

MCMASTER UNIVERSITY, CANADA

**ESWI**

SCIENTISTS FIGHTING INFLUENZA AND OTHER ACUTE RESPIRATORY VIRUSES

Subscribe to the ESWI newsletter

Subscribe here!

Follow ESWI



If you have any questions about #ESWI2025, please contact:

**Dagmar de Graef**  
Head of Operations and registrations  
[dagmar.degraef@eswi.org](mailto:dagmar.degraef@eswi.org)

**Annick Mannaerts**  
Head of Programmes  
[annick.mannaerts@eswi.org](mailto:annick.mannaerts@eswi.org)

**Goretti Cortina**  
Head of Media and Press Relations  
[goretti.cortina@eswi.org](mailto:goretti.cortina@eswi.org)

© ESWI 2024 - [Privacy statements](#)

